View insights.
Physicists have long sought to marry general relativity and quantum mechanics – now some reckon experiments that probe the way each theory treats time could finally make it happen.
Humans are unrivaled in the area of cognition. After all, no other species has sent probes to other planets, produced lifesaving vaccines, or created poetry. How information is processed in the human brain to make this possible is a question that has drawn endless fascination, yet no definitive answers.
Our understanding of brain function has changed over the years. But current theoretical models describe the brain as a “distributed information-processing system.” This means it has distinct components that are tightly networked through the brain’s wiring. To interact with each other, regions exchange information though a system of input and output signals.
However, this is only a small part of a more complex picture. In a study published last week in Nature Neuroscience, using evidence from different species and multiple neuroscientific disciplines, we show that there isn’t just one type of information processing in the brain. How information is processed also differs between humans and other primates, which may explain why our species’ cognitive abilities are so superior.
TNX to hard work of Coma Science Group and collaborators from Milano and Paris within Human Brain Project!
A group of drugs commonly used to treat erectile dysfunction may be able to boost the effect of chemotherapy in esophageal cancer, according to new research funded by Cancer Research UK and the Medical Research Council.
A group of drugs commonly used to treat erectile dysfunction may be able to boost the effect of chemotherapy in esophageal cancer, according to new research funded by Cancer Research UK and the Medical Research Council.
This research, published today (Tuesday) in Cell Reports Medicine, found that the drugs, known as PDE5 inhibitors can reverse chemotherapy resistance by targeting cells called cancer-associated fibroblasts (CAFs) residing in the area surrounding the tumor.
Although this is early discovery research, PDE5 inhibitors combined with chemotherapy may be able to shrink some esophageal tumors more than chemotherapy could alone, tackling chemotherapy resistance, which is one of the major challenges in treating esophageal cancer.
Scientists at the Institute of Cancer Research in London have developed a new light-activated “photoimmunotherapy” that could help treat brain cancer. The key is a compound that glows under light to guide surgeons to the tumor, while near-infrared light activates a cancer-killing mechanism.
The new study builds on a common technique called Fluorescence Guided Surgery (FGS), which involves introducing a fluorescent agent to the body which glows under exposure to light. This is paired with a synthetic molecule that binds to a specific protein, such as those expressed by cancer cells. The end result is tumors that glow under certain lighting conditions or imaging, guiding surgeons to remove the affected cells more precisely.
For the new study, the researchers gave the technique an extra ability – killing the cancer as well. They added a new molecule that binds to a protein called EGFR, which is often mutated in cases of the brain cancer glioblastoma. After the fluorescence has helped surgeons remove the bulk of the tumor, they can shine near-infrared light on the site, which switches the compound into a tumor-killing mode by releasing reactive oxygen species. The idea is to kill off any remaining cells that could – and often do – stage an aggressive comeback after surgery.
